Audit of factor VIIa for bleeding resistant to conventional therapy following complex cardiac surgery

Canadian Journal of Anesthesia

Volumn 53, Issue 9, 2006, Pages 926-933

  McCall, Peter ^a   Story, David A ^a   Karapillai, Darshi ^a  

^a AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; PROTAMINE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

ADULT; AGED; AORTA VALVE; ARTICLE; AUSTRALIA; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CLINICAL PROTOCOL; CRYOPRECIPITATE; ERYTHROCYTE CONCENTRATE; FEMALE; HEART SURGERY; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEDICAL RECORD REVIEW; MORBIDITY; MORTALITY; PERIOPERATIVE PERIOD; PLASMA TRANSFUSION; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRIVATE HOSPITAL; STERNOTOMY; THROMBOCYTE TRANSFUSION; UNIVERSITY HOSPITAL;

AGED; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; FACTOR VII; FEMALE; HUMANS; MALE; MEDICAL AUDIT; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 33750698658     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03022836     Document Type: Article

References (30)

1. Franchini M, Zaffanello M, Veneri D. Recombinant factor VIIa. An update on its clinical use. Thromb Haemost 2005; 93: 1027-35.
2. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005; 33: 883-90.
3. Raivio P, Suojaranta-Ylinen R, Kuitunen AH. Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery. Ann Thorac Surg 2005; 80: 66-71.
4. Hyllner M, Houltz E, Jeppsson A. Recombinant activated factor VII in the management of life-threatening bleeding in cardiac surgery. Eur J Cardiothorac Surg 2005; 28: 254-8.
5. Karkouti K, Beattie WS, Wijeysundera DN, et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion 2005; 45: 26-34.
6. Aggarwal A, Malkovska V, Catlett JP, Alcorn K. Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage. Thromb J 2004; 2: 9.
7. von Heymann C, Redlich U, Jain U, et al. Recombinant activated factor VII for refractory bleeding after cardiac surgery - a retrospective analysis of safety and efficacy. Crit Care Med 2005; 33: 2241-6.
8. Diprose P, Herbertson MJ, O'Shaughnessy D, Gill RS. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth 2005; 95: 596-602.
9. von Heymann C, Hotz H, Konertz W, Kox WJ, Spies C. Successful treatment of refractory bleeding with recombinant factor VIIa after redo coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2002; 16: 615-6.
10. Despotis G, Avidan M, Lublin DM. Off-label use of recombinant factor VIIA concentrates after cardiac surgery. Ann Thorac Surg 2005; 80: 3-5.
11. Spiess BD. Transfusion of blood products affects outcome in cardiac surgery. Semin Cardiothorac Vasc Anesth 2004; 8: 267-81.
12. Karkouti K, Wijeysundera DN, Yau TM, et al. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion 2004; 44: 1453-62.
13. Martinowitz U, Michaelson M; The Israeli Multidisciplinary rFVIIa Task Force. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost 2005; 3: 640-8.
14. National Health and Medical Research Council. Clinical Practice Guidelines on the Use of Blood Components (red blood cells, platelets, fresh frozen plasma, cryoprecipitate). Canberra: Commonwealth of Australia, 2002. Available from URL; www.nhmrc.gov.au.
15. Bevan DH. Cardiac bypass haemostasis: putting blood through the mill. Br J Haematol 1999; 104: 208-19.
16. Blome M, Isgro F, Kiessling AH, et al. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost 2005; 93: 1101-7.
17. Paparella D, Brister SJ, Buchanan MR. Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med 2004; 30: 1873-81.
18. French CJ, Bellomo R, Angus P. Cryoprecipitate for the correction of coagulopathy associated with liver disease. Anaesth Intensive Care 2003; 31: 357-61.
19. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematol 2003; 122: 10-23.
20. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, et al.; British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126: 11-28.
21. Thompson AR. When all else fails to stop massive bleeding from trauma. J Thromb Haemost 2005; 3: 638-9.
22. Engoren MC, Habib RH, Zacharias A, Schwann TA, Riordan CJ, Durham SJ. Effect of blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg 2002; 74: 1180-6.
23. Clark AD, Gordon WC, Walker ID, Tait RC. 'Last-ditch' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang 2004; 86: 120-4.
24. Hardy JF. Managing uncontrolled hemorrhage in trauma and surgery: a novel and promising approach. Can J Anesth 2002; 49(Suppl 2): S4-6.
25. Hall TS, Brevetti GR, Skoultchi AJ, Siner JC, Gregory P, Spotnitz AJ. Re-exploration for hemorrhage following open heart surgery differentiation on the causes of bleeding and the impact on patient outcomes. Ann Thorac Cardiovasc Surg 2001; 7: 352-7.
26. Boffard KD, Riou B, Warren B, et al.; NavoSeven Trauma Study Group. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005; 59: 8-15; discussion 15-8.
27. Enomoto TH, Thorborg P. Emerging off-label uses for recombinant activated factor VII: grading the evidence. Crit Care Clin 2005; 21: 611-32.
28. de Jong E, Friederich PW, Vlasuk GP, et al. Activation of coagulation by administration of recombinant factor VIIa elicits interleukin 6 (IL-6) and IL-8 release in healthy human subjects. Clin Diag Lab Immunol 2003; 10: 495-7.
29. Spahn DR, Tucci MA, Makris M. Is recombinant FVIIa the magic bullet in the treatment of major bleeding? Br J Anaesth 2005; 94: 553-5.
30. Goodnough LT, Lublin DM, Zhang L, Despotis G, Eby C. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 2004; 44: 1325-31.